Peguy Schmidt, DO
Child & Adolescent Psychiatry · Detroit, MINPI 1619400371
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 22 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Alkermes, Inc. at 34.2% of the total. Reporting peaked in 2019 at $263 and has fallen 65.2% since, to $91 in 2025.
Across 22 payments — averaging $20.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$157
- Johnson & Johnson$65
- Neurocrine Biosciences, Inc.$54
- Otsuka America Pharmaceutical, Inc.$53
- Indivior Inc.$36
- Lundbeck LLC$32
- plus $62 from 2 others
What the payments were for
- Food & beverage$459100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 7 | $157 |
| Johnson & Johnson | 2 | $65 |
| Neurocrine Biosciences, Inc. | 3 | $54 |
| Otsuka America Pharmaceutical, Inc. | 3 | $53 |
| Indivior Inc. | 2 | $36 |
| Lundbeck LLC | 2 | $32 |
| Avanir Pharmaceuticals, Inc. | 2 | $32 |
| E.r. Squibb & Sons, L.L.C. | 1 | $31 |
How this compares
$459 in reported general payments places this provider in the 75th percentile of 73 child & adolescent psychiatry providers in Michigan.
See all child & adolescent psychiatry providers in Michigan →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lurasidone Hcl | 20 | $4,635 |
| Aripiprazole | 57 | $2,208 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 19 | $1,386 |
| Quetiapine Fumarate | 26 | $1,297 |
| Clonidine Hcl ErClonidine Hcl | 17 | $1,136 |
| Clonazepam | 27 | $904 |
| Guanfacine Hcl ErGuanfacine Hcl | 16 | $726 |
| Trazodone Hcl | 80 | $710 |
| Thioridazine Hcl | 15 | $671 |
| Risperidone | 39 | $585 |
| Fluoxetine Hcl | 60 | $522 |
| Escitalopram Oxalate | 41 | $408 |
| Hydroxyzine Hcl | 17 | $379 |
| Mirtazapine | 21 | $376 |
| Divalproex Sodium | 14 | $323 |
Paid to pharmacies, not to this prescriber.
Other child & adolescent psychiatry in Detroit
- Cecilia Astorga-SwitzerDetroit$75
- Megan FojtikDetroit$30
- Birgit AmannTroy$980K
- David VillanuevaSterling Heights$140K
- Carol Crouch-RossLivonia$24K
- Robert GarciaNorthville$24K
- Gerald SchmukerSpring Lake$11K
- Mohammad JafferanySaginaw$10K
- Sridevi KodaliLivonia$7K
- Viken MatossianHowell$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.